Back
Compare AU
Compare GXAI vs. DRUG
Compare shares and ETFs on the ASX that you can trade on Pearler.
Overview
When it comes to investing in the Australian stock market, shares and ETFs are a popular choice. Two options in the ASX are GXAI and DRUG. In this comparison, we'll delve into these options across various dimensions to help you make an informed investment decision.
Community Stats
GXAI | DRUG | |
|---|---|---|
Popularity | Low | Low |
Pearlers invested | 455 | 80 |
Median incremental investment | $764.99 | $736.96 |
Median investment frequency | Monthly | Monthly |
Median total investment | $2,006.25 | $2,210.88 |
Average age group | > 35 | > 35 |
Key Summary
GXAI | DRUG | |
|---|---|---|
Strategy | N/A | DRUG.AX was created on 2016-08-04 by BetaShares. The fund's investment portfolio concentrates primarily on health care equity. The ETF currently has 184.38m in AUM and 55 holdings. DRUG.AX aims to track the performance of an index (before fees and expenses) that comprises the largest global healthcare companies (ex-Australia), hedged into Australian dollars. |
Top 3 holdings | Global X Artificial Intelligence ETF (100 %) | AUD - AUSTRALIA DOLLAR (0 %) BRL - BRAZILIAN REAL (0 %) CHF - SWISS FRANC (0 %) |
Top 3 industries | Other (75.91 %) Communication Services (33.53 %) Health Care (23.80 %) | |
Top 3 countries | United States (72.30 %) Switzerland (11.31 %) United Kingdom of Great Britain and Northern Ireland (5.57 %) | |
Management fee | 0 % | 0.57 % |
Key Summary
GXAI | DRUG | |
|---|---|---|
Issuer | BetaShares | |
Tracking index | Nasdaq Global ex-Australia Healthcare Hedged AUD Index - AUD | |
Asset class | Stock | ETF |
Management fee | 0 % | 0.57 % |
Price | $16.05 | $9.87 |
Size | N/A | $199.202 million |
10Y return | N/A | 109.11 % |
Annual dividend/βdistribution yield (5Y) | 3.23 % | 1.82 % |
Market | ASX | ASX |
First listed date | 09/04/2024 | 08/08/2016 |
Purchase fee | $6.50 | $6.50 |
Community Stats
GXAI | DRUG | |
|---|---|---|
Popularity | Low | Low |
Pearlers invested | 455 | 80 |
Median incremental investment | $764.99 | $736.96 |
Median investment frequency | Monthly | Monthly |
Median total investment | $2,006.25 | $2,210.88 |
Average age group | > 35 | > 35 |
Pros and Cons
GXAI | DRUG | |
|---|---|---|
Pros |
|
|
Cons |
|
|
GXAI | DRUG |
|---|---|
Exposure to 1 market and 1 sector only | Exposure to more markets and sectors |
Lower price growth | Higher price growth |
Higher dividend/distribution yield | Lower dividend/distribution yield |